Showing results (2361-2370 of 2,573) with videos related to
Sort By:
Pageof 258
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2025
Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin ChemotherapyJoshua Millstein, Shahrad R Rassekh, Austin L Brown, et al.Gene Therapy|March 27, 2025
Optimization of adeno-associated viral (AAV) gene therapies vectors for balancing efficacy, longevity and safety for clinical applicationNeel Mehta, Rénald Gilbert, Parminder S Chahal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung CancerD Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.Lung Cancer (Amsterdam, Netherlands)|November 19, 2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancerDavid E Gerber, D Ross Camidge, Daniel Morgensztern, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain MetastasesDaniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|June 12, 2026
Liposomal lipid nanoparticles containing dihydrosphingomyelin exhibit improved stability and extended hepatic and extrahepatic transfectionSuiyang Liao, Kevin Fox, Alexandra Birkenshaw, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief ReportDong-Wan Kim, Sang-We Kim, D Ross Camidge, et al.Canadian Journal of Kidney Health and Disease|March 9, 2017
Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort StudyKelly R McMahon, Shahrad Rod Rassekh, Kirk R Schultz, et al.Pediatric Blood & Cancer|February 27, 2013
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in childrenH Visscher, C J D Ross, S R Rassekh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic studyStephen Leong, Roger B Cohen, Daniel L Gustafson, et al.Pageof 258